For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.
Yosemite's investment portfolio shows a bias towards "first in class" or potentially curative "last in class" therapies. This indicates a higher tolerance for innovation risk, betting on novel modalities and groundbreaking science over safer, incremental advances.
As an investor stepping into an interim CEO role, success hinges on leveraging long-standing relationships with the early team. Proactively building trust with newer employees through informal chats is also critical, proving personal connection trumps formal authority.
Yosemite provides unrestricted grants to academic scientists, de-risking novel research and building relationships. This early support creates a unique deal flow engine, leading to investment opportunities in companies that later spin out from this foundational work.
While focused on oncology, Yosemite's portfolio company Tune Therapeutics is using epigenetic editing to develop a functional cure for Hepatitis B. This is a strategic cancer play, as chronic Hepatitis B is the leading global cause of liver cancer.
Unlike traditional biotech VCs, Yosemite allocates a quarter of its fund to digital health. This reflects its mission to reduce cancer mortality across the entire patient journey, funding solutions for pricing transparency, financial toxicity, and post-approval care.
Yosemite's oncology focus stems from Reed Jobs' experience with his father Steve Jobs' pancreatic cancer. However, the firm deliberately adopts a broad, pan-cancer investment strategy, recognizing the interconnectedness of cancer biology across different tissue types.
After serving as interim CEO at portfolio company Tune Therapeutics, VC Dan McHugh gained a profound appreciation for operational challenges. He now emphasizes deeper diligence on areas like manufacturing process development, which he previously understood only at a surface level.
While biotech hubs like Boston offer a larger talent pool, companies in emerging hubs may benefit from higher employee retention. With fewer local competitors, top talent is less likely to be poached, creating more stable teams, a trade-off investors consider.